[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Hospitalier Régional d'Orléans\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":687},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,46,78,105,136,157,186,211,234,260,287,314,341,372,403,428,462,484,508,531,553,577,604,631,658],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100552521","assessment-of-t-cell-response-and-in-vitro-proof-of-concept-of-t-cell-engineering-in-chronic-eskd-patients-100552521",false,"NCT06474169","Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic ESKD Patients.","Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic End-stage Kidney Disease Patients.","LYMPHOVIR-IRCT","Inclusion Criteria:\n\n1. Male or female ≥ 18 years\n2. Informed participants who did not object to participating in the study\n\nExclusion Criteria:\n\n1. Chronic progressive infections\n2. Prior organ transplantation (including bone marrow transplantation)\n3. Previous treatment with immunosuppressive agents (such as Rituximab, Eculizumab, Tacrolimus or Ciclosporin, Cellcept or Imurel) within 2 years prior to inclusion\n4. Participant under guardianship, curatorship or deprived of liberty\n5. Pregnant or breastfeeding women",true,"ALL","18 Years",{"count":22,"type":23},100,"ESTIMATED","OBSERVATIONAL","This is a comparative, prospective, non-interventional study to evaluate immune response in patients with chronic kidney disease. The primary objective is to define immunodeficiency (phenotype and function of T cells) in patients with end-stage kidney disease. The second objective is to provide an in-vitro proof-of-concept of T-cell engineering in the context of end-stage kidney disease.\n\nThe study population was patients with chronic kidney disease.",[27],"Chronic Kidney Diseases",[29,30,31,32],"end-stage kidney disease","T-cells response","Immunodeficiency","Proof of concept of T-cell therapy","RECRUITING","2026-06-22",{"date":36,"type":37},"2026-06-25","ACTUAL",{"date":39,"type":37},"2024-11-27",{"date":41,"type":23},"2026-12",{"name":43,"class":44},"Centre Hospitalier Régional d'Orléans","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100643156","efficacy-of-high-flow-humidified-oxygen-hfho-in-apneic-oxygenation-for-apnea-testing-a-comparison-with-continuous-positive-airway-pressure-cpap-100643156","NCT07640009","Efficacy of High-Flow Humidified Oxygen (HFHO) in Apneic Oxygenation for Apnea Testing: A Comparison With Continuous Positive Airway Pressure (CPAP)","Efficacy of High-Flow Humidified Oxygen in Apneic Oxygenation During Apnea Testing Compared With Continuous Positive Airway Pressure: A Randomized Multicenter Crossover Trial","APNEAFLO2W","Inclusion Criteria:\n\n* Adult intensive care unit patients\n* fulfilling all criteria for clinical brain death, for whom confirmation of the absence of spontaneous breathing requires performance of an apnea test\n* And for whom consent to participate in the study was sought from a trusted person or a family member\n\nExclusion Criteria:\n\n* History of chronic obstructive pulmonary disease (COPD) classified as GOLD stage III or IV.\n* Current extracorporeal life support, including veno-arterial (VA) or veno-venous (VV) extracorporeal membrane oxygenation (ECMO).\n* PaO₂\u002FFiO₂ ratio ≤ 150 on the most recent arterial blood gas analysis, obtained within 24 hours prior to the screening visit.\n* Presence of at least one clear or absolute contraindication to the procurement of at least one organ.\n* Presence of a high cervical spinal cord injury.\n* Patient in the prone position and\u002For with a contraindication to placement in the supine position at 30°.\n* Minor patient.\n* Protected adult under legal guardianship or curatorship.\n* Individual under judicial protection (safeguard of justice).\n* Individuals deprived of liberty.\n* Individual not covered by a social security or health insurance system.\n* Pregnant or breastfeeding woman.",{"count":55,"type":23},28,"INTERVENTIONAL",[58],"NA","Brain death (BD) is characterized by a severe brain injury resulting in irreversible loss of all brain and brainstem functions, while other organs may remain viable. The diagnosis of BD is based on the presence of coma, absence of brainstem reflexes, and absence of spontaneous breathing confirmed by an apnea test. In France, the apnea test is mandatory prior to organ procurement. The apnea test aims to demonstrate that hypercapnia, a strong ventilatory stimulus, does not induce any respiratory movements.\n\nIn current practice, the apnea test is performed by disconnecting the patient from mechanical ventilation for 8-10 minutes while administering oxygen. Oxygenation strategies during apnea vary across French centers. Although the use of continuous positive airway pressure (CPAP) is recommended, a substantial proportion of tests are still performed without positive end-expiratory pressure (PEEP) effect, using either an open T-piece or an intratracheal oxygen catheter. These methods are associated with a higher risk of complications, such as hypoxemia, and potential adverse effects on organ function, which is particularly relevant in the context of organ donation.\n\nHumidified high-flow oxygen (HHFO), delivered via a specialized device connected to the endotracheal tube, provides high flow rates (up to 60 L\u002Fmin), allows precise adjustment of the fraction of inspired oxygen (FiO₂ up to 1.0), and generates a minimal PEEP effect. HHFO is routinely used in intensive care units. While its feasibility during apnea testing has been reported, its efficacy during BD diagnosis has not been well evaluated.\n\nPreliminary observations in intensive care patients with clinical brain death suggest that HHFO can be safely used during the apnea test, allowing achievement of hypercapnia and confirmation of absence of spontaneous respiration while maintaining better oxygenation compared with conventional oxygen delivery via an open T-piece.\n\nThis study aims to evaluate the efficacy of HHFO for apneic oxygenation during the apnea test, in comparison with the recommended method using CPAP.",[61],"Death, Brain",[63,64,65,66,67],"Intensive Care Unit","Humidified high-flow oxygen therapy","Continuous positive airway pressure","Apnea testing","Brain death","NOT_YET_RECRUITING","2026-06-05",{"date":71,"type":37},"2026-06-10",{"date":73,"type":23},"2026-09-15",{"date":75,"type":23},"2028-09-15",{"name":43,"class":44},4,{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":45},"100620404","influence-of-handedness-on-upper-limb-recovery-100620404","NCT07357181","Influence of Handedness on Upper Limb Recovery","Impact of Manual Preference on Motor Deficits After Stroke","HANDISTROKE","Inclusion Criteria:\n\n1. Confirmed unilateral recent stroke (less than 5 days).\n2. Age 18 years and older.\n3. Participant or proxy does not object to participation\n\nExclusion Criteria:\n\n1. Prior stroke with residual motor sequelae.\n2. Pre-stroke upper-limb deficit.\n3. Follow-up at 6 months not planned at Orléans.\n4. Protected adult (guardianship\u002Fcuratorship), person under legal protection, or deprived of liberty.\n5. Pregnant or breastfeeding woman.",{"count":87,"type":23},500,"This prospective, single-center observational study evaluates whether handedness is associated with upper-limb motor recovery after a recent unilateral stroke. Adults admitted to the stroke unit with a confirmed unilateral stroke within 5 days are included if they do not object to participation. Upper-limb impairment is assessed early after stroke and at 6 months using standardized clinical scales. Handedness is determined by self-report, and the Edinburgh Handedness Inventory is administered when feasible. The main hypothesis is that left-handed participants may show better upper-limb motor recovery at 6 months than right-handed participants, potentially due to differences in brain motor network lateralization.",[90],"Stroke",[90,92,93,94,95,96,97],"Handedness","Motricity","Upper Limb","Manual preference","Motor impairment","Motor recovery",{"date":99,"type":37},"2026-06-08",{"date":101,"type":37},"2026-06-02",{"date":103,"type":23},"2028-10",{"name":43,"class":44},{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":56,"phases":115,"briefSummary":116,"conditions":117,"keywords":123,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":45},"100587044","ultrasound-evaluation-of-cardiac-function-during-spontaneous-breathing-trials-100587044","NCT06923267","Ultrasound Evaluation of Cardiac Function During Spontaneous Breathing Trials","Ultrasound Evaluation of Cardiac Function During Three Spontaneous Breathing Trials in Intensive Care Unit : A Prospective Interventional Study","ATARI","Inclusion Criteria:\n\n* Intubated patient undergoing invasive mechanical ventilation for at least 24 hours and scheduled for a spontaneous breathing trial\n* Richmond Agitation Sedation Scale (RASS) between -1 and +1\n* Patient at high risk of re-intubation with at least one of the following criteria:\n\n  * Underlying cardiac disease (left ventricular dysfunction with left ventricular ejection fraction ≤ 45%, documented ischemic heart disease, chronic atrial fibrillation, known history of cardiogenic pulmonary edema)\n  * Underlying respiratory disease (COPD, Emphysema, bronchial dilatation, asthma, obesity\u002Fhypoventilation syndrome, restrictive lung disease)\n\nExclusion Criteria:\n\n* Neuromuscular pathology (myasthenia type) preceding hospitalization\n* Pregnant or breast-feeding women\n* Patient already included in the study\n* Protected person (under guardianship or curatorship)\n* Person under court protection\n* Person not affiliated to a social security scheme",{"count":114,"type":23},24,[58],"The goal of this clinical trial is to evaluate the evolution of a cardiac ultrasound index (E\u002FE') during 3 spontaneous breathing trials in Intensive Care Unit (ICU) adults (over 18 years) patients at risk for weaning failure. The main objective is to find out which spontaneous breathing trial is the least demanding in terms of heart work.\n\nInvestigators will compare 3 consecutive spontaneous breathing trials in a random order to see if one is superior to the others.\n\nParticipants will not have to perform any specific procedure apart from breathing without respiratory support during the spontaneous breathing trial. During these trials, the investigator will perform cardiac ultrasound measurements.",[118,119,120,121,122],"Weaning Invasive Mechanical Ventilation","Weaning-induced Pulmonary Edema","Weaning Failure of Mechanical Ventilation","Spontaneous Breathing Test","Intensive Care Units (ICUs)",[124,125,126,127],"Humidified high flow","Cardiac ultrasound","Spontaneous breathing trial","T-Piece","2026-05-21",{"date":130,"type":37},"2026-05-22",{"date":132,"type":37},"2025-04-30",{"date":134,"type":23},"2027-05",{"name":43,"class":44},{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":56,"phases":145,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":154,"leadSponsor":156,"locationsCount":45},"100636365","study-of-tolerance-to-the-application-of-cold-plasma-in-the-treatment-of-chronic-wounds-100636365","NCT07564739","Study of Tolerance to the Application of Cold Plasma in the Treatment of Chronic Wounds","PLASMA-SAFE","Inclusion Criteria:\n\n1. Men or women.\n2. Aged 18 years or older.\n3. Chronic wound or ulceration.\n4. Wound measuring 5 to 100 cm² of arterial or venous origin.\n5. Evolution \\> 4 weeks.\n6. With less than 30% necrosis.\n7. Able to give informed written consent.\n8. Blood pregnancy test for women of childbearing age.\n\nExclusion Criteria:\n\n1. Tumor wounds\n2. Dialysis\n3. Patients requiring surgical revascularization\n4. Severe heart failure (NYHA III-IV) or acute myocardial infarction.\n5. Wounds or ulcers located less than 10 cm from the patient's airways and respiratory tract\n6. Severe renal failure defined as creatinine clearance \\\u003C20 mL\u002Fmin calculated according to the MDRD\n7. Patients with severe hepatic impairment (class C) according to the Child Pugh score\n8. Unstable liver disease (defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormality.\n9. Active malignant tumor\n10. Patients who, in the investigator's opinion, are at significant risk of suicide\n11. Any pre-existing physical or mental condition that may interfere with the patient's ability to comply with the administration schedule and\u002For protocol assessments, or that may compromise the patient's safety.\n12. Persons covered by Articles L.1121-5 to L.1121-8 and L.1122-1-2 of the Public Health Code (including minors and protected adults)\n13. Protected person (under guardianship or curatorship)\n14. Person under judicial protection\n15. Persons deprived of their liberty\n16. Persons not affiliated with a social security system\n17. Women who are pregnant or breastfeeding, or who plan to become pregnant or breastfeed during the study.\n18. Patients participating in another clinical trial evaluating a treatment\n19. Allergy to the dressings used in the trial",{"count":144,"type":23},40,[58],"Chronic wounds affect many patients, with no downward trend in recent decades. This is a significant economic and social issue, and this condition has an impact on functional disabilities and quality of life, especially among the elderly. Diagnosis is essentially clinical, and there are many causes, but 90% of leg ulcers, for example, are primarily vascular in origin. There are wounds of traumatic, post-operative, and vascular origin, as well as pressure sores. The main purpose of invasive tests is to objectively determine the cause (arterial damage) or to check for underlying osteitis. Chronic wounds are usually infected or colonized by bacteria from the skin and digestive flora. There is no indication for antibiotic therapy in the treatment of wounds. Nursing staff play an important role in therapeutic management, which must be carried out in harmony with other healthcare professionals, such as general practitioners and specialists. This management has two main goals: to accelerate the epidermalization of chronic wounds, or even their healing, and to limit local and general complications, the recurrence of which remains the most difficult to control. There are many types of healing dressings available, adapted to each type of ulceration: fibrinous, necrotic, superinfected, etc.\n\nNevertheless, innovative solutions can accelerate healing, thereby reducing hospital stays, disabilities associated with chronic wounds, and complications such as skin-related septicemia. Research efforts may focus on the use of growth factors, for example, for old or stubborn forms of the disease, despite proper medical treatment, or on any other innovative technique.\n\nThe properties of cold plasma appear to be suitable for the treatment of chronic wounds, as has been demonstrated in cell models, animal models, and with argon plasma in several countries around the world on an experimental basis in humans.\n\nThe GREMI in Orléans has acquired internationally recognized expertise in the technique of cold helium plasma. The combination of this applied research laboratory and the Infectious Diseases Department of the Orléans University Hospital has led to the development of relationships that have resulted in the proposal to conduct this study, based in its first phase on the evaluation of the medical device's tolerance.",[148,149],"Wound","Chronic Ulcer","2026-05-12",{"date":152,"type":37},"2026-05-15",{"date":150,"type":37},{"date":155,"type":23},"2027-09",{"name":43,"class":44},{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":56,"phases":167,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":45},"100587866","validation-of-the-foot-health-status-questionnaire-in-french-language-100587866","NCT06933953","Validation of the Foot Health Status Questionnaire in French Language","Psychometric Validation of the Foot Health Status Questionnaire in French Language","FHSQ-Fr","Inclusion Criteria:\n\n1. Patients coming to IFRES in Alençon (61) France for a pedicure or podiatry appointment,\n2. Age \\>= 18\n3. knowing how to speak, read and write French.\n\nExclusion Criteria:\n\n1\\. Have already taking part in this research before the proposition to get in.",{"count":166,"type":23},150,[58],"A French foot health survey showed that 73% of people examined felt pain and 38% don't left their home, which suggest a reduction in their life's quality and autonomy. Developed by Paul Bennett, FHSQ is a foot health-specific self administrated questionnaire. It sensitively detects changes in patients' foot health status, whatever their pathology, across multidimensional concepts of their quality of life. Actually, more than 150 scientific publications have cited it. Reliable and valid, it has already been translated and validated in multiple languages, but not in French. The subject of this study is to validate the translated and cross-cultural adapted French version FHSQ-fr through its psychometric results of validity and reliability. The study follows a 2-stage methodology.\n\nThe first, already completed, consisted of (back)translating the Australian FHSQ questionnaire into French by a scientific committee in order to obtain a pre-final version.\n\nThe second is to validate this final version using appropriate statistical analysis, including correlations studies with other French validated questionnaires, to determine its psychometric characteristics.",[170],"Patients With Foot Problems",[172,173,174,175,176,177],"Surveys and Questionnaires","FHSQ French translation","Health status","Foot","Validity","Reliability","2026-04-29",{"date":180,"type":37},"2026-04-30",{"date":182,"type":37},"2025-03-31",{"date":184,"type":23},"2027-02",{"name":43,"class":44},{"id":187,"slug":188,"hasResults":12,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":210},"100572861","antimicrobial-therapy-for-difficult-to-treat-pseudomonas-aeruginosa-100572861","NCT06738771","Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa","Antimicrobial Therapy for Infections Due to Pseudomonas Aeruginosa With Difficult-to-treat Resistance: a Real-world, Prospective, Multicenter Cohort Study","ADDICT","Inclusion Criteria:\n\n* All patients aged 18 or over and requiring intravenous definite antimicrobial therapy for a DTR P. aeruginosa infection\n\nExclusion Criteria:\n\n* Cystic fibrosis\n* P. aeruginosa DTR colonization or P. aeruginosa DTR infection not requiring definitive intravenous antibiotic therapy\n* Protected person (under guardianship or curatorship)\n* Persons under court protection\n* Persons deprived of liberty\n* Opposition expressed for participation in the study",{"count":195,"type":23},600,"The primary objective of the ADDICT study is to assess and compare the clinical efficacy of available options for antimicrobial therapy (new beta-lactam\u002Fbeta-lactamase inhibitor combination, cefiderocol or older agents such as aminoglycosides and colistin) in unselected patients with infection due to difficult-to-treat P. aeruginosa.",[198,199,200,201,202,203],"Pseudomonas Infections","Pseudomonas Aeruginosa","Prognosis","Drug Resistance, Multiple, Bacterial","Antibacterial Agents","Beta-lactam Antibiotics",{"date":180,"type":37},{"date":206,"type":37},"2025-03-11",{"date":208,"type":23},"2027-01",{"name":43,"class":44},48,{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":220,"conditions":221,"keywords":223,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":233,"locationsCount":45},"100612767","interest-of-continuous-subcutaneous-apomorphine-in-parkinsonian-patients-at-the-end-of-life-100612767","NCT07257861","Interest of Continuous Subcutaneous Apomorphine in Parkinsonian Patients at the End of Life","OPTIDOM","Inclusion Criteria:\n\n1. Person (or trusted person\u002Frelative if patient is unable) who has agreed to participate in the study\n2. Patient of legal age\n3. Advanced Parkinson's disease with apomorphine pump indication\n4. Use of HH for palliative reasons\n5. Loss of orality (discontinuation of oral treatments)\n6. Hoehn \\&Yahr score in OFF = 5 (bilateral and axial symptoms in the absence of levodopa)\n\nExclusion Criteria:\n\n1. Apomorphine pump already in use\n2. Opposition to the introduction of an apomorphine pump\n3. Protected person (under guardianship or curatorship)\n4. Person under court protection\n5. Persons deprived of liberty\n6. Persons not affiliated to a social security scheme\n7. Pregnant or breast-feeding woman",{"count":219,"type":23},80,"Care for Parkinson's patients at the end of life is far from optimal, particularly due to specificities linked to the disease itself, often unknown to non-specialists.\n\nA study carried out at the CHU Rennes on data covering the period 2006-2018 showed that only 132 patients died in this hospital, two-thirds of whom came from home. In 42% of cases, antiparkinsonian treatment was stopped before death without specialist advice (palliative or neurological), with the corollary of the appearance of a dopaminergic withdrawal syndrome (or pseudo-neuroleptic malignant syndrome) in a high proportion of these patients. Neuroleptic pseudo-malignant syndrome is a major cause of discomfort. If left untreated, it can precipitate death in particularly distressing conditions for the patient, his or her family and caregivers.\n\nThe Rennes study also suggests that Parkinson's patients rarely die in hospital. In fact, work carried out by FNEHAD on data for 2022 showed that 1,800 Parkinson's patients were cared for in HAH in France during that same year, mainly for palliative care or heavy nursing reasons. Half of these patients died.\n\nEnd-of-life management of Parkinson's disease therefore requires local clinical and pharmacological expertise. A recent observational study suggests that the use of a subcutaneous apomorphine pump brings substantial benefits in terms of clinical comfort, both motor and non-motor, as well as relief for family and friends, easier nursing care for the nursing team, and in some cases, renewed communication.\n\nSuch care can be provided in the home, and must necessarily be multidisciplinary, combining palliative expertise, provided by Home Hospitalization (HH) teams, with technical and Parkinson's expertise, provided by Home Healthcare Providers (HHPs) experienced in managing the apomorphine pump, in liaison with the referral team.",[222],"Parkinson Disease",[224,225,226],"Apomorphine","Parkinson","End of life","2026-03-19",{"date":229,"type":37},"2026-03-23",{"date":231,"type":37},"2026-02-02",{"date":184,"type":23},{"name":43,"class":44},{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":56,"phases":244,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":45},"100561371","body-composition-and-acute-stroke-100561371","NCT06589297","Body Composition and Acute Stroke","Prognostic Value for Predicting Functional Outcome Bioimpedancemetry and Temporal Muscle Measurement in Acute Stroke","PREDISTROKE","Inclusion Criteria:\n\n* volunteer stroke patients in acute phase\n* Age ≥ 18 years\n* Having had a brain MRI\n* Able to understand assessment guidelines\n* Not having objected to participate in the study after being duly informed\n\nExclusion Criteria:\n\n* Person under tutorship or curatorship\n* Person under court protection\n* Persons deprived of their liberty\n* Pregnant or breastfeeding women\n* Have a pacemaker or defibrillator",{"count":243,"type":23},250,[58],"Body composition appears to be a prognostic factor for the severity and functional outcome of stroke patients. In this study the prognostic value of two bioimpedance parameters will be studied (skeletal mass index and phase angle) and two temporal muscle measurements (thickness and surface area) to predict the functional outcome of patients at discharge and at 6 months",[247],"Acute Stroke",[90,249,250,251,252],"Body composition","Bioimpedancemetry","Temporal muscle","Sarcopenia","2026-01-29",{"date":231,"type":37},{"date":256,"type":37},"2024-10-10",{"date":258,"type":23},"2028-06",{"name":43,"class":44},{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":268,"minAge":20,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":56,"phases":271,"briefSummary":272,"conditions":273,"keywords":275,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":286,"locationsCount":45},"100561368","cannabidiol-into-breastmilk-100561368","NCT06589258","Cannabidiol Into Breastmilk","Study of the Passage of (CBD) Into Breast Milk and Its Biological Impact on Breast-fed Children","CBD-ALLT","Inclusion Criteria:\n\n* Women over 18\n* Breastfeeding CBD user\n* Having given written informed consent\n\nExclusion Criteria:\n\n* Women who do not understand French well\n* Women with a psychiatric or dual pathology that prevents proper participation in the study,\n* Women under protective supervision (guardianship\u002Fcuratorship),\n* Women under court protection,\n* Women not affiliated to a social security scheme","FEMALE",{"count":270,"type":23},60,[58],"Really few data published to date on the passage of CBD into breast milk. The investigators known that 17.5 percent of the French human being between 18 and 34 years old consume CBD and among this, nearly half are women. None official French data to say how many French breastfeeding mothers consume CBD. CBD is a legal, psychoactive but not psychoaddictive substance. CBD's pharmacokinetic and pharmacodynamics make us fear that CBD could easily go through mother's milk. No published data available on possible effect in breast-fed child, not even on possible biological passage in breast-fed child. The aim of his study is to evaluate the passage of CBD in blood and milk at different moments of the breastfeeding (mothers) and its possible found in the infants'urine.",[274],"Breast Feeding",[276,277,278,279,280],"cannabidiol","Breast milk","Breast-feeding","Breast-feed children","PK POP",{"date":282,"type":37},"2026-01-30",{"date":284,"type":37},"2025-10-06",{"date":103,"type":23},{"name":43,"class":44},{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":56,"phases":297,"briefSummary":298,"conditions":299,"keywords":301,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":45},"100470723","feasibility-of-end-tidal-oxygen-concentration-monitoring-during-preoxygenation-for-intubation-in-the-intensive-care-unit-100470723","NCT05409573","Feasibility of End-tidal Oxygen Concentration Monitoring During Preoxygenation for Intubation in the Intensive Care Unit.","Feasibility of End-tidal Oxygen Concentration Monitoring During Preoxygenation for Intubation in the Intensive Care Unit. First Part, Preliminary Study of the IMPROVE Global Project","IMPROVE-Pre","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Requiring an intubation in ICU for acute respiratory failure defined as a respiratory rate ≥ 25\u002Fmin or clinical signs of respiratory distress or hypoxemia defined as oxygen requirement ≥ 15L\u002Fmin or FiO2 ≥80% to maintain SpO2 ≥92% or a PaO2\u002FFiO2 ratio \\\u003C100 mmHg\n* With preoxygenation by noninvasive ventilation\n\nExclusion Criteria:\n\n* Intubation for cardiac arrest\n* EtO2 monitoring not available\n* Pulsed oxygen saturation monitoring specific for the study not available\n* Preoxygenation by high-flow nasal oxygen therapy or bag-mask ventilation\n* Allergy to lidocaine (for local nasal anesthesia)\n* Previously\n* Patient not affiliated or excluded from social protection, or under law protection (namely minors, pregnant or breastfeeding women, persons deprived of their liberty by court or administrative decision)\n* Previously included in the study",{"count":296,"type":23},30,[58],"Intubation is a common procedure in the intensive care unit. Hypoxemia is the most frequent complication of this procedure.\n\nMonitoring the end-tidal of oxygen is recommended in operating room (OR). End-tidal of oxygen (EtO2) \\>90% is an indication of a correct preoxygenation.\n\nThis monitoring is not used in routine in intensive care unit (ICU). There is no recommendation on the monitoring of end-tidal of oxygen in intensive care unit. In practice, clinicians use pulsed oxygen saturation (SpO2) to determine whether the patient is sufficiently preoxygenated. However, this parameter is not a good indicator of a correct preoxygenation.\n\nIn the OR, patients are compliant during the preoxygenation period and the measure of EtO2 with the face mask monitor is considered reliable because i) mask leakage is minimal and ii) the patient can breathe slowly and regularly.\n\nTheses conditions are not available in critical ill patients requiring emergency intubation. EtO2 measured on the facemask may not reflect true EtO2.\n\nThis concern about the reliability of EtO2 measurement via the facemask justifies that we conduct a study to compare EtO2 measured on a facemask (facemask EtO2) to EtO2 measured in pharynx (via e nasopharyngeal catheter).\n\nThe aim of this study is to determine whether the measurement of EtO2 on facemask is reliable in patients in ICU.",[300],"Critically Ill",[302,303,304,305,306],"Preoxygenation","intubation","end-tidal of oxygen","intensive care unit","critically ill patients","2026-01-28",{"date":253,"type":37},{"date":310,"type":37},"2022-12-23",{"date":312,"type":23},"2027-12",{"name":43,"class":44},{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":56,"phases":325,"briefSummary":326,"conditions":327,"keywords":329,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":45},"100618695","ultrasound-guided-carpal-tunnel-infiltration-comparison-between-the-manual-method-and-a-robot-assisted-method-100618695","NCT07334964","Ultrasound-Guided Carpal Tunnel Infiltration: Comparison Between the Manual Method and a Robot-Assisted Method","Ultrasound-Guided Carpal Tunnel Infiltration: Comparison Between the Manual Method and a Robot-Assisted Method - A Pilot, Comparative, Randomized Study","ICCERO","Inclusion Criteria:\n\n1. Age ≥ 18 and ≤ 75 years.\n2. Clinical diagnosis of carpal tunnel syndrome.\n3. Indication for corticosteroid injection as determined by investigator.\n4. Moderate to severe carpal tunnel syndrome defined by a pain score on the Visual Analogue Scale (VAS) ≥ 4 (at baseline and on day 0).\n5. Signed informed consent.\n\nExclusion Criteria:\n\n1. Known allergy to corticosteroids or povidone-iodine (Betadine)\n2. Probable or ongoing systemic or local infection\n3. History of injection in the affected wrist within the last 6 months\n4. Thenar eminence atrophy\n5. Trauma requiring surgery or immobilization\n6. History of carpal tunnel surgery\n7. Protected person (under guardianship or curatorship)\n8. Person under judicial protection\n9. Person deprived of liberty\n10. Person not affiliated with a social security scheme\n11. Pregnant or breastfeeding woman\n12. Person participating in a drug trial","75 Years",{"count":324,"type":23},20,[58],"This study aims to assess the feasibility, safety, and accuracy of a robotic arm-assisted carpal tunnel injection in comparison with the conventional ultrasound-guided method, prior to conducting a larger-scale study.\n\nThe use of a robotic arm to maintain the ultrasound probe in position could provide valuable assistance to the physician. The procedure would no longer require the involvement of a third person in addition to the physician. To date, no study has compared these two approaches.",[328],"Carpal Tunnel Syndrome",[330,331,332],"carpal tunnel syndrome","robot-assited-ultrasonography","carpal tunnel injection","2026-01-06",{"date":335,"type":37},"2026-01-12",{"date":337,"type":37},"2025-11-25",{"date":339,"type":23},"2027-02-25",{"name":43,"class":44},{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":351,"conditions":352,"keywords":359,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":45},"100616445","cohort-study-on-medical-students-mental-health-100616445","NCT07305701","Cohort Study on Medical Students' Mental Health","Mental Health of Medical Students in Orleans: a Cohort Study of a New Faculty","OSMOSE","Inclusion Criteria:\n\n* Students who have been enrolled in first year of health studies at the University of Orléans\n* Aged 18 or over\n\nExclusion Criteria:\n\n* Does not speak French\n* Person under legal guardianship\n* Person deprived of liberty\n* Person under guardianship or trusteeship",{"count":350,"type":23},10000,"The main objective of this study is to identify risk factors for depression among medical students by comparing them to students who completed their first year but did not enter the medical program (students not accepted into the second year of medical school).\n\nMajor Depressive Disorder (MDD) will be assessed using a validated tool: the Composite International Diagnostic Interview Short-Form (CIDI-SF).\n\nThis a prospective, longitudinal, cohort study. The plan is to inform each new cohort of students at the Orléans University Hospital medical school for 10 years. It is estimated that 5,000 to 10,000 students will be able to participate in the study.\n\nA link to access the study questionnaire will be sent to students by email via the registrar's office, with one email per week for four weeks. The email will contain a link to a web page where the questionnaire can be completed. The questionnaire will be available online on computers or smartphones for six weeks: from mid-October to the end of November. The questionnaire will be completed each year for the duration of the study or until the student completes their studies.\n\nDuration of the inclusion period: 10 years Duration of participation for each participant: maximum 12 years Total duration of the study: 22 years As the cohort progresses, longitudinal analyses may be conducted to study the evolution of various disorders over time, adjusting for known confounding factors. Following the initial analyses of this study, a new interventional study will be set up to identify students at risk and offer them appropriate care.",[353,354,355,356,357,358],"Major Depressive Disorder","Generalized Anxiety Disorder","Suicidal Ideation","Alcoholism","Marijuana Abuse","Loneliness",[360,361,362,363],"Students","Medical students","depression","epidemiology","2025-12-26",{"date":366,"type":37},"2025-12-31",{"date":368,"type":37},"2025-10-22",{"date":370,"type":23},"2047-10-31",{"name":43,"class":44},{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":381,"conditions":382,"keywords":390,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":45},"100580823","effects-of-phytocannabinoids-on-immune-response-and-autophagy-during-chronic-immune-mediated-inflammatory-diseases-100580823","NCT06842316","Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases","In Vitro Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases","pCB-IMIDs","Inclusion Criteria:\n\n1. Male or female ≥ 18 years old\n2. Diagnosis confirmed by a rheumatologist of RA or spondyloarthropathy (with or without IBD) or psoriatic arthritis (with or without active psoriasis) or systemic lupus erythematosus or Sjögren's disease\n3. Patient who has expressed consent to participate in the study\n4. Patients affiliated to social security\n5. Treatments authorized as part of routine care: non-steroidal anti-inflammatory drugs (NSAIDs), level 1 to 3 analgesics, local corticosteroids, oral corticosteroid therapy (daily dose ≤15 mg\u002Fd), 5-aminosalicylic acid, salazopyrine, methotrexate, leflunomide, hydroxychloroquine, biotherapies and targeted therapies.\n\nExclusion Criteria:\n\n1. Patient who received intravenous corticosteroid therapy less than 4 weeks ago\n2. Patient receiving oral corticosteroid therapy with a daily dose \\>15 mg\u002Fday\n3. Consumption of CBD and\u002For recreational cannabis and\u002For positive saliva test for cannabis consumption and\u002For CBD\n4. Pregnant and lactating women\n5. Persons under guardianship or curatorship",{"count":22,"type":23},"Cannabis, in addition to its psychotropic properties, could have anti-inflammatory and immunomodulatory effects. Phytocannabinoids (pCBs) are a group of molecules naturally secreted by the cannabis plant. The major pCBs are cannabidiol (CBD) and Δ9-tetrahydrocannabinol Δ9 (THC). Only THC has psychotropic effects, which CBD does not have. Alongside these two main components, there is a wide variety of other molecules, such as other pCBs and terpenes which could increase the effects on immune system through synergistic interactions between these different compounds (\"entourage effect\").In vivo, pCBs essentially interfere with the endocannabinoid system, acting on many ubiquitous receptors, present on a significant number of different cell types. Numerous published studies show that pCBs have immunomodulatory and anti-inflammatory properties by acting on several of these receptors, whether through modulation of the immune response of different cell types, effects on cytokine networks, reduction of innate and adaptive responses and\u002For impact on cell survival or death (autophagy, proliferation\u002F apoptosis). The Immune-Mediated Inflammatory Diseases (IMIDs) affect 5 to 7% of the general population in Western countries, involve different organs (joints, skin, digestive tract) but share the same inflammatory mechanisms resulting from a dysregulation of the immune response. Our research focuses on the identification of the most effective phytochemical profile of pCBs, allowing an optimal effect on chronic inflammatory pathologies of interest among immune-mediated chronic inflammatory diseases (IMIDs). The pCB-IMIDs project is therefore part of an innovative translational project, around new therapeutic applications of medical cannabis (CannAppIMIDs). In our study, we will include 100 patients with one of IMIDs among Rheumatoid Arthritis, spondylarthritis, psoriatic arthritis, Sjogren disease and systemic lupus, at different stage and with different treatments. After patient's consent we will collect for research purposes an additional 40 ml of blood during a routine care blood test. Mononuclear and polynucleated blood cells will be exposed in vitro to different full-spectrum pCB extracts (full spectrum extract) including a CBD dominant and low THC extract (\\\u003C0.2%), 1 dominant THC extract, 1 balanced THC\u002FCBD extract and 1 dominant CBG extract. In this cross-sectional study, our objective will be to assess the biological effects of different pCB compositions on inflammatory profiles (concentrations of pro and anti-inflammatory cytokines and chemokines) and modulations of expression profiles (autophagy, apoptosis, and cannabinoid receptor expression profile).",[383,384,385,386,387,388,389],"Inflammatory Disorder of Immune System","Spondylitis, Ankylosing","Arthritis, Rheumatoid","Arthritis, Psoriatic","Inflammatory Bowel Diseases","Sjogren's Syndrome","Lupus Erythematosus, Systemic",[391,392,393,394],"IMIDs","phytocanabinoid","inflammatory effect","blood cells","2025-12-22",{"date":397,"type":37},"2025-12-30",{"date":399,"type":37},"2025-04-10",{"date":401,"type":23},"2027-04-09",{"name":43,"class":44},{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":407,"acronym":408,"eligibilityCriteria":409,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":410,"enrollmentInfo":411,"targetDuration":4,"studyType":56,"phases":413,"briefSummary":414,"conditions":415,"keywords":417,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":422,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":45},"100583749","neuromodulatory-effects-of-audio-proprio-phonatory-reinforcement-training-on-subjective-tinnitus-demonstrated-by-high-density-electroencephalogram-hd-eeg-100583749","NCT06880367","Neuromodulatory Effects of Audio-proprio-phonatory Reinforcement Training on Subjective Tinnitus, Demonstrated by High-density Electroencephalogram (HD EEG)","PHONACOU","Inclusion Criteria:\n\n* Person who agreed to participate in the study and gave consent\n* Aged ≥ 18 years and \\\u003C 85 years\n* Suffering from subjective tinnitus for more than 3 months\n* Have a score on the THI questionnaire taken at T0 greater than or equal to 38\n* Be equipped with a smartphone compatible with the Siopi application and a computer connection for videoconference sessions\n* Have answered the questionnaires on the Siopi application: THI, VAS-D and associated questions and insomnia severity index\n* Have committed to diligently following the study protocol, including independent training\n* Have agreed not to take other new treatments for tinnitus throughout the duration of the study\n* Able to understand and carry out assessment instructions.\n\nExclusion Criteria:\n\n* Patient suffering from objective tinnitus\n* Current port of white noise generators\n* Patient having consulted phoniatrics more than twice or having participated in more than two sound-mediated workshop sessions\n* Bilateral hearing loss \\> 40 dB uncorrected on an audiogram or having declared serious or severe hearing loss on Siopi questionnaire, with or without prosthetic correction\n* New therapy introduced less than 2 months ago\n* Psychatric disorders causing auditory hallucinations\n* Protected person (under guardianship or curatorship)\n* Person under judicial protection\n* Person deprived of liberty\n* Person not affiliated to a social security system\n* Pregnant or breastfeeding woman\n* Person participating in a drug study","84 Years",{"count":412,"type":23},56,[58],"Our ecological approach to neuromodulation in the field of \"acouphonology\" empowers tinnitus patients to act as their own source of sound stimuli through audio-proprio-phonatory reinforcement (APPR). By engaging in self-phonations, individuals uncoverthe vast potential for sound production, which can effectively mask their tinnitus or induce residual inhibition, all without relying on external sources.\n\nThis clinical study aims to illustrate the positive impact of audio-proprio-phonatory reinforcement training on individuals suffering from chronic subjective tinnitus. This will be further supported and quantified through high-definition electroencephalography (HD EEG) as we explore the relationship between changes in connectivity within specific brain regions and the varying degrees of response to the therapeutic protocol.",[416],"Tinnitus, Subjective",[418,419,420,421],"Subjective tinnitus","neuromodulation","audio-proprio-phonatory reinforcement","high-density electroencephalogram",{"date":397,"type":37},{"date":424,"type":37},"2025-03-18",{"date":426,"type":23},"2028-09-18",{"name":43,"class":44},{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":432,"acronym":433,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":56,"phases":436,"briefSummary":437,"conditions":438,"keywords":440,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":457,"startDateStruct":458,"completionDateStruct":459,"leadSponsor":461,"locationsCount":45},"100583182","trophallergen-prick-tests-pt--influence-of-food-sample-shelf-life-on-the-reproducibility-of-pt-results-100583182","NCT06872996","Trophallergen Prick Tests (PT) : Influence of Food Sample Shelf Life on the Reproducibility of PT Results","TROPHAPRICK","Inclusion Criteria:\n\n1. Aged 18 and over.\n2. Having a diagnosis of food allergy(ies) due to one or more of the food allergen studied, previously made by an allergologist, of grade 2 to 3 according to the Ring and Messmer classification.\n3. Having given consent to participate in the study.\n\nThe diagnosis is made by the allergologist of the department due to the presence of a compatible clinical history implicating the tested allergen, the presence of evidence of sensitization to the allergen (positive prick-test and\u002For positive specific IgE assays), or even a positive oral allergen reintroduction test.\n\nExclusion Criteria:\n\n1. Anaphylactic reaction dating less than 6 weeks\n2. Hospitalization for asthma in the past 3 months\n3. History of grade 4 anaphylactic reaction according to the Ring and Messmer classification.\n4. Systemic antihistamine treatment in the 7 days preceding the test\n5. Systemic beta-blocker treatment on the day of the test.\n6. Protected person (under guardianship or curatorship)\n7. Person under judicial supervision\n8. Persons deprived of liberty\n9. Person not affiliated with a social security insurance\n10. Pregnant or breastfeeding women",{"count":22,"type":23},[58],"Prick tests (PT) are the standard skin tests used in the investigation of immediate IgE-mediated food allergies. Their use as a first-line tool in allergological investigations is strongly recommended by the European Academy of Allergy and Clinical Immunology (EAACI). These tests involve locally reproducing histamine release manifestations in the epidermis by superficially introducing an allergen to confirm or rule out its role in the onset of clinical symptoms compatible with an allergy. During the diagnostic management and follow-up of patients with food allergies, the technique used is the \"prick to prick\" method, due to the lack of reliable access to many standardized commercial food extracts. This method involves piercing the food with a sterile lancet (to deposit food content on its surface) and then making a superficial skin puncture with the same device on the anterior surface of the forearm to introduce a tiny fraction of the food and its proteins into the epidermis, where mast cells are present. Simultaneously, a positive control and a negative control are performed. The tests are read after 15 to 20 minutes by measuring the size in millimeters of the resulting papules and erythema. A PT for the tested allergen is considered positive if the average diameter of the resulting papule is 3 mm or more and\u002For at least half the size of the positive control papule. The procedure is well-tolerated, allowing it to be performed at any age, in both hospital and outpatient settings. The risk of a systemic reaction has been evaluated at 0.008%, with no severe reactions observed.\n\nThis method, performed with native foods (unprocessed food, uncontaminated foods), either raw or cooked (depending on the nature of the allergen being tested), is preferred over the use of commercial extracts (standardized commercial allergen preparations) due to its better sensitivity and specificity, the high cost of commercial extracts, and the lack of commercial extracts for certain foods. For practical reasons, given the wide variety of possible allergens, and to most accurately reproduce the exposure that caused the reaction, the most common approach is to ask the patient to bring their own foods for testing. These foods should be brought in a fresh state. However, situations where the patient is offered a food PT but does not have fresh native foods are common. Indeed, many patients forget to bring them. Similarly, during a consultation to explore a respiratory or drug allergy, the interview may lead to the detection of a food allergy that needs to be tested at the same time. Given the delays in allergology consultations, the severity of food allergy symptoms, and the potential risk of delayed diagnosis, all allergists involved in managing food allergies are led to create a library of food samples stored either in a dry state (e.g., nuts, peanuts, cereal flours) or frozen for perishable foods (meats, shellfish, fruits, vegetables). To our knowledge, after reviewing the literature, no guidelines for best practices regarding the storage of these food samples for PT purposes have been established by scientific societies. Moreover, while the impact of freezing and thawing methods on the denaturation of food proteins is known, the effect of freezing and its duration on the sensitivity and specificity of PT is poorly understood.\n\nThe objective of our study is to evaluate the reproducibility of PT results between those performed with fresh foods and those performed with preserved foods at different storage dates in participants who have experienced anaphylaxis of at least grade 2 according to the Ring and Messmer classification.",[439],"Food Allergy",[441,442,443,444,445,446,447,448,449,450,451,452,453,454,455,456],"Prick test","Skin test","Trophallergen","Food sample","Fresh","Frozen","Fruit","vegetables","Meat","Alpha-gal","Arachide","Leguminous plant","Milk","Nuts","Fish","Seafood",{"date":397,"type":37},{"date":399,"type":37},{"date":460,"type":23},"2027-10-10",{"name":43,"class":44},{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":468,"eligibilityCriteria":469,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":470,"targetDuration":4,"studyType":56,"phases":472,"briefSummary":473,"conditions":474,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":477,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":483},"100580193","impact-of-pain-from-injectables-antiretroviral-treatments-in-hiv-1-patients-based-on-the-injection-site-ventrogluteal-or-dorsogluteal-and-the-use-or-non-use-of-virtual-reality-headset-100580193","NCT06834113","Impact of Pain From Injectables Antiretroviral Treatments in HIV-1 Patients Based on the Injection Site (Ventrogluteal or Dorsogluteal) and the Use or Non-use of Virtual Reality Headset","Impact of Two Types of Interventions (Ventrogluteal Versus Dorsogluteal Injection Site; Virtual Reality Headset: Presence or Absence) on Pain After Injections of Vocabria® (Cabotegravir) and Rekambys® (Rilpivirine) in Patients Infected With Human Immunodeficiency Virus -1","VIHINJECT","Inclusion Criteria:\n\n* Patient aged at least 18 years;\n* Patient infected with HIV-1;\n* Patient virologically controlled (VL \\\u003C 50 copies\u002Fml);\n* Patient scheduled to receive treatment with cabotegravir and rilpivirine (naïve patients) or currently on injectable cabotegravir and rilpivirine, prescribed by their referring physician.\n\nExclusion Criteria:\n\n* Patient(s) on another injectable antiretroviral treatment;\n* Patient participating in another clinical trial with medication;\n* Patient(s) with epilepsy;\n* Patient on antidepressant treatment;\n* Patient(s) with psychiatric or behavioral disorders;\n* Patient(s) with a history of dizziness and motion sickness that prevents the use of virtual reality headset;\n* Patient(s) with visual and hearing impairments that prevent the use of virtual reality headset;\n* Patient(s) deprived of liberty, under guardianship or under curatorship;\n* Patient(s) not affiliated with a social security scheme;\n* Pregnant or breastfeeding women.",{"count":471,"type":23},120,[58],"This is a multicenter, randomized, open-label study with a cross-over design. The objective of this project is to compare the intensity of pain induced by injectable antiretroviral (ARV) treatment (Cabotegravir® and Rilpivirine®) in patients infected with HIV-1, depending on the injection site and whether or not they are wearing a virtual reality headset. The reference group being the dorsogluteal injection without headset.\n\nParticipants who meet the study criteria will be randomized into 1 of 24 sequences. A sequence is composed by 4 injections procedures: dorsogluteal intramuscular injection (A), ventrogluteal intramuscular injection (B), dorsogluteal intramuscular injection with virtual reality headset (C), ventrogluteal intramuscular injection with virtual reality headset (D).\n\nEach patient will be their own witness and will experience the 4 intramuscular injection procedures of injectable antiretroviral.\n\nThe study population are patients carrying HIV-1 and being monitored for this pathology, eligible (naïve patients) or already under Cabotegravir® (CAB) and Rilpivirine® (RPV) injectable treatment.",[475,476],"HIV I Infection","Injection Pain",{"date":397,"type":37},{"date":479,"type":37},"2025-01-24",{"date":481,"type":23},"2026-09-24",{"name":43,"class":44},5,{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":18,"sex":268,"minAge":20,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":56,"phases":492,"briefSummary":493,"conditions":494,"keywords":496,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":502,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":45},"100573433","effect-of-physical-activity-andor-probiotics-on-body-composition-and-physiological-parameters-in-women-100573433","NCT06746220","Effect of Physical Activity and\u002For Probiotics on Body Composition and Physiological Parameters in Women","AP-Pro-Fem","Inclusion Criteria:\n\n1. Being female\n2. Age ≥ 18 years old\n3. Have a BMI between 18.5 and 30 kg\u002Fm2\n4. Be registered as a student at the University of Orléans\n5. Be non-athletic\n6. Have no contraindication to the practice of physical activity\n7. All participants must sign informed consent before the start of the study\n\nExclusion Criteria:\n\n1. Smokers \\>10 cigarettes per day\n2. Having treatment for a pathology at the time of inclusion\n3. Taking a probiotic supplement during the last month prior to inclusion\n4. Practice physical activity regularly (150 minutes\u002Fweek of moderate physical activity according to the WHO)\n5. Participant under guardianship or curators\n6. Pregnant or breastfeeding women\n7. Menopausal women\n8. Allergy to any excipient known to be present in the probiotic or placebo formulation",{"count":471,"type":23},[58],"This is a prospective, comparative, double-blind, randomized, monocentric study.\n\nThe objective of this project is to evaluate the effects on health of probiotic supplementation (PS) with or without physical activity (PA). Participants who meet the study criteria will be randomized into 4 groups: probiotic and physical activity group (A+), probiotic and non-physical activity group (A-), placebo and physical activity group (T+), placebo and non-physical activity group (T-).\n\nThe probiotics used are Lactibiane® Reference provided by Pileje Laboratory. The study population are healthy women (university students) who do not practice sports. A total of 120 participants will participate.\n\nAt inclusion, each participant will undergo a medical examination, collect microbiota and salivary samples and perform different tests (questionnaires, assessments of strength and endurance). Then, a follow up phase will last 6 weeks. Each participant will receive a pillbox containing capsules (probiotic or placebo in a double-blind manner). Participants which randomized in the PA groups (A+ and A-) will perform 2 physical activity sessions per week for 6 weeks. At the end of this follow up phase, tests conducting during inclusion will be performed again.",[495],"Healthy Women",[497,498,499,500,501],"Microbiota","Probiotics","Physical activity","Health","women",{"date":397,"type":37},{"date":504,"type":37},"2024-09-16",{"date":506,"type":23},"2027-12-15",{"name":43,"class":44},{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":514,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":516,"targetDuration":4,"studyType":56,"phases":518,"briefSummary":519,"conditions":520,"keywords":522,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":525,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":45},"100525118","effect-of-inspiratory-muscle-training-in-obstructive-sleep-apnea-syndrome-100525118","NCT06117579","Effect of Inspiratory Muscle Training in Obstructive Sleep Apnea Syndrome.","Effect of Inspiratory Muscle Training on Daytime Sleepiness in Obstructive Sleep Apnea Syndrome : Prospective Randomized Controlled Trial","NOCTURNE","Inclusion Criteria:\n\n* patients over 18 years of age with\n* OSA with an Apnea Hypopnea Index ≥ 5 requiring CPAP\n\nExclusion Criteria:\n\n* Sleep apnea of neurological or mixed origin,\n* Contraindication to or refusal of CPAP,\n* Cognitive disorders,\n* protected persons (under guardianship or curatorship),\n* persons under court protection,\n* persons not affiliated to a social security scheme\n* pregnant or breast-feeding women.",{"count":517,"type":23},58,[58],"Sleep apnea-hypopnea syndrome is a sleep-related respiratory disorder characterized by partial or total interruptions in breathing during sleep. The majority of syndromes involve an obstructive mechanism (OSA), caused by a reduction in the caliber of the upper airway (UA), most often associated with hypotonia of the surrounding muscles, preventing air from entering the UA during inspiration. The clinical consequences of this syndrome are excessive fatigue and daytime sleepiness, which have a negative impact on the quality of life of patients.\n\nDespite the positive results on apnea-hypopnea index and daytime sleepiness of continuous positive airway pressure (today's reference treatment), its 3-year compliance rate (i.e 59.9% according to a study by Abdelghani et al points to the need to develop other associated therapies.\n\nSeveral studies have demonstrated the efficacy of physiotherapy, such as physical activity and oro-pharyngeal muscle strengthening, notably on the apnea-hypopnea index and daytime sleepiness measured by the Epworth scale.\n\nFew studies have investigated the effect of inspiratory muscle training (IMT), even though the use of the inspiratory musculature (i.e. the diaphragm) is a means of supplementing the peri-pharyngeal muscles, as it helps to maintain the permeability of the upper airways. Inspiratory muscle training (IMT) could therefore be considered as part of the physiotherapeutic management of the OSA. The heterogeneity of current results concerning IMT in OSA , but above all the lack of evidence that it is dangerous, means that new clinical studies could be carried out in an attempt to demonstrate its efficacy. Our research hypothesis is therefore as follows: Implementing an inspiratory muscle strengthening protocol in patients suffering from OSA can reduce daytime sleepiness.",[521],"Obstructive Sleep Apnea of Adult",[523,524],"Obstructive Sleep Apnea","Inspiratory muscle training",{"date":397,"type":37},{"date":527,"type":37},"2024-06-26",{"date":529,"type":23},"2027-01-25",{"name":43,"class":44},{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":19,"minAge":322,"maxAge":4,"enrollmentInfo":539,"targetDuration":4,"studyType":56,"phases":541,"briefSummary":542,"conditions":543,"keywords":544,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":547,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":45},"100506061","calf-circumference-versus-x-ray-absorptiometry-in-the-diagnosis-of-sarcopenia-in-elderly-hospitalized-patients-100506061","NCT05869487","Calf Circumference Versus X-ray Absorptiometry in the Diagnosis of Sarcopenia in Elderly Hospitalized Patients","Evaluation of a Diagnostic Method: Calf Circumference Versus X-ray Absorptiometry in the Diagnosis of Sarcopenia in Elderly Hospitalized Participants","PAPY-SARCM","Inclusion Criteria:\n\n* Age greater than or equal to 75 years\n* Hospitalization in a medical department or in the follow-up care or rehabilitation department of the Hospital Center of Orléans\n* Presence of an etiological criterion of undernutrition\n* Presence of a decrease in muscle strength\n\nExclusion Criteria:\n\n* Presence of one of two phenotypic criteria for undernutrition other than sarcopenia, which are body mass index less than 22 kilogram per square meter and weight loss (≥ 5 percent over 1 month or ≥ 10 percent over 6 months or ≥10 percent compared with usual weight before the disease).\n* Refusal to participate in the study\n* Patient under legal protection\n* Impossible to perform X-ray absorptiometry (behavioral problems, functional constraints to climb on the DXA machine)\n* Person not affiliated to a social security system",{"count":540,"type":23},298,[58],"This is a prospective single-center study to evaluate a diagnostic method. The main objective of the study is to evaluate the performance of calf circumference as a diagnostic method for sarcopenia in hospitalized elderly people, compared to a gold standard method which is X-ray absorptiometry. The study population are hospitalizing participants aged 75 years and older with an indication to search for sarcopenia.",[252],[252,545,546],"Absorptiometry","Photon",{"date":397,"type":37},{"date":549,"type":37},"2023-12-11",{"date":551,"type":23},"2027-04-11",{"name":43,"class":44},{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":557,"acronym":558,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":560,"targetDuration":4,"studyType":56,"phases":562,"briefSummary":563,"conditions":564,"keywords":567,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":571,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":45},"100398754","early-verticalization-of-the-patient-with-acute-respiratory-distress-syndrome-assessment-of-feasibility-and-safety-100398754","NCT04472260","Early Verticalization of the Patient With Acute Respiratory Distress Syndrome: Assessment of Feasibility and Safety.","STAND_ARDS1","Inclusion Criteria:\n\n* Major patient \\> 18 years of age\n* ARDS patients with PaO2\u002FFiO2 ratio \\\u003C 150 at any time within 24 hours prior to the screening visit\n* Hemodynamically stable patient with mean arterial pressure (MAP) \\> 65 mmHg maintained without vasopressor or with norepinephrine at a dosage of less than 0.5 µg\u002Fkg\u002Fmin.\n* Patient having already undergone at least 1 but less than 5 PP sessions\n* Patient under continuous intravenous sedation (IVSE) or not responding to simple order.\n* Written consent of support person or family.\n\nExclusion Criteria:\n\n* Pregnant women (positive pregnancy test during screening)\n* Breastfeeding women\n* Protected Majors\n* Body weight greater than 198 kg (bed load limit)\n* Patient with one or two lower limbs amputated at the trans tibial or upper level\n* Contraindication to standing (orthopedic fracture, neurological instability with the presence of an intracranial pressure sensor or an external ventricular shunt....)\n* Deep venous thrombosis of the lower limbs with curative anticoagulation for less than 48 hours\n* Hemodynamic instability (MAP \\\u003C 65 mm Hg) despite the use of norepinephrine at a dosage equal or greater than 0.5 µg\u002Fkg\u002Fmin.\n* Person under guardianship or trusteeship\n* Non-beneficiary patient of a health insurance plan\n* Moribund patient",{"count":561,"type":23},32,[58],"Acute Respiratory Distress Syndrome (ARDS) is defined according to the Berlin definition (1) as diffuse lung damage occurring in patients with a predisposing risk factor.\n\nPositioning in the prone position (PP) has been shown to decrease mortality in patients with moderate to severe ARDS.\n\nHowever, this technique is not without deleterious effects such as ventilator-associated pneumonia, endotracheal tube obstruction, development of pressure ulcers, and increased workload for the caregivers.\n\nThere are other positioning techniques such as the \"upright\" position, which simulates a relative verticality, which allows to increase the effects of the prone position and even in some patients to improve oxygenation without the PP in the acute phase of ARDS.\n\nHowever, given the revolution caused by the use of PP in ARDS patients, verticalization have not been studied in more details.\n\nToday, there is a bed on the market that allows patients to be truly upright without having to transfer them to a tilt table.\n\nThe investigators believe that raising ARDS patients in the acute phase is safe and feasible in routine practice. In this research protocol comparing PP and verticalization in a crossover trial design in acute ARDS patients, the investigators want to show that this technique can be safe and feasible, with the same effects on oxygenation as PP.",[565,566],"Acute Respiratory Distress Syndrome","Prone Position",[568,569,63,570],"Acute respiratory distress syndrome","Verticalization","Prone position",{"date":397,"type":37},{"date":573,"type":37},"2021-10-15",{"date":575,"type":23},"2026-07-14",{"name":43,"class":44},{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":581,"acronym":582,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":584,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":586,"conditions":587,"keywords":592,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":598,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":45},"100374822","study-of-autophagy-and-the-effects-of-galig-gene-products-in-hiv-1-infected-patients-who-are-under-antiretroviral-therapy-since-primary-infection-chronic-phase-or-never-treated-100374822","NCT04160455","Study of Autophagy and the Effects of GALIG Gene Products in HIV-1 Infected Patients Who Are Under Antiretroviral Therapy Since Primary-infection, Chronic Phase, or Never Treated.","ATGALIG-HIV","Inclusion Criteria:\n\nGeneral criteria:\n\n* Age \\>=18 years\n* Man or woman\n* Infected with HIV-1 (and not co-infected with HIV-2)\n* Followed at Orleans' Regional Hospital\n* Patient belonging to one of the predefined cohorts\u002Fgroups (see below)\n* Patient having provided a written consent\n\nSpecific profiles of HIV-infected patients for the ATGALIG-HIV study:\n\nCohort A: patients on suppressive antiretroviral therapy (HIV RNA \\\u003C50 copies \u002F ml for at least 4 years) initiated during the chronic phase, divided into 2 groups according to the following criteria:\n\n* group A1: CD4 count less than 500 cells \u002F ml at the time of inclusion in the study\n* group A2: CD4 count above 500 cells \u002F ml at the time of inclusion in the study Cohort B: patients on suppressive antiretroviral therapy (HIV RNA \\\u003C50 copies \u002F ml for at least 4 years) initiated since the primary-infection (within 4 months after acute infection)\n\nCohort C: patients with detectable HIV RNA, naïve of antiretroviral, but who have an indication to start antiretroviral therapy, divided into the following 3 groups:\n\n* group C1: HIV diagnosis made during primary infection (within 4 months of infection)\n* group C2: HIV diagnosis made during the chronic phase (more than 1 year after contamination), with CD4 count above 200 cells\u002Fml at the time of inclusion in the study\n* group C3: HIV diagnosis made during the chronic phase (more than 1 year after contamination), with CD4 count less than 200 cells\u002Fml at the time of inclusion in the study Cohort D: patients who have undetectable plasma HIV RNA (HIV RNA \\\u003C50 copies \u002F ml ) without antiretroviral therapy, either spontaneously (HIV controllers or elite controllers) or after treatment interruption (post-treatment controllers)\n\nExclusion Criteria:\n\n* Patient unable, according to the investigator, to meet the requirements of the protocol\n* Pregnant or lactating woman\n* Patient with a history of inflammatory bowel disease, malignancy, intestinal ischemia, malabsorption or other gastrointestinal dysfunction that, in the judgment of the investigator, could interfere with the interpretation of the results.\n* Presence of coagulation abnormality or unexplained bleeding history\n* Treatment with oral or injectable anticoagulant (curative or preventive)\n* Patient covered by Article L.1121-5 to L.1121-8 and L.1122-1-2 of the French Public Health Code (including minors and protected adults)\n* Patient under guardianship or curatorship\n* Patient who uncovered by French health insurance Patient participating in another clinical trial, evaluating a treatment",{"count":585,"type":23},180,"Little is known about autophagy during HIV infection. Recently, two different teams reported important dysfunctions of autophagy in HIV-infected patients despite sustained suppressive antiretroviral therapy. As altered autophagy is strongly linked to cellular senescence and chronic inflammation, two hallmarks of HIV-infected patients despite long-term suppressive antiretroviral therapy, it is important to improve our knowledge in the area.\n\nOur main objective is to determine whether all or part of mononuclear cell subpopulations (CD4+ and CD8+ T lymphocytes, and monocytes) exhibit a defect in autophagy function in a cohort of HIV-infected patients who are virologically-controlled (plasma HIV RNA \\\u003C50 copies \u002F ml) either spontaneously (i.e. HIV controllers or post-treatment controllers) or after they started antiretroviral therapy at different time points (i.e. at the acute or chronic phases), as compared with a control group (i.e. uninfected healthy blood donors).",[588,589,590,591],"Autophagy","Galectins","HIV Infections","Highly Active Antiretroviral Therapy",[593,594,595,596,597],"Antiretroviral therapy","basal autophagy","GALIG gene","HIV","apoptosis",{"date":397,"type":37},{"date":600,"type":37},"2019-11-07",{"date":602,"type":23},"2039-11-07",{"name":43,"class":44},{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":56,"phases":613,"briefSummary":614,"conditions":615,"keywords":617,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":630},"100590924","effect-of-the-sitting-out-of-bed-in-an-arm-chair-position-in-icu-on-functional-recovery-among-ventilated-patients-100590924","NCT06973746","Effect of the \"Sitting Out of Bed in an Arm-chair Position\" in ICU on Functional Recovery Among Ventilated Patients","Effect of the \"Sitting Out of Bed in an Arm-chair Position\" in ICU on Functional Recovery Among Ventilated Patients: a Prospective Randomized Controlled Trial","STORM","Inclusion Criteria:\n\n1. Patient \\> 18 years old\n2. Patient on invasive mechanical ventilation for more than 24 hours\n3. Patient in recovery phase with a RASS score greater than \"-3\" for more than 12 hours\n4. Stay expected to last 48 hours\n5. Patient has never been placed in a chair during this hospitalization in intensive care.\n6. Fragility score \\\u003C 6, during the month preceding admission to intensive care\n7. Patient (or support person\u002Frelative if patient is unable to participate) who has agreed to take part in the study.\n\nExclusion Criteria:\n\n1. Patient with an absolute and non-resolving contraindication to chair positioning\n\n   1. Fracture or orthopedic disorder contraindicating mobilization out of bed\n   2. Obesity with body mass index greater than 45 kg\u002Fcm2\n   3. Sacral eschar stage greater than 2\n2. Patient using a wheelchair for mobility (i.e. paraplegic patient or patient with progressive neurological pathology).\n3. Patient treated with veno-venous or veno-arterial ECMO at the time of screening.\n4. Moribund patient\n5. Encephalic death\n6. Acute polyradiculoneuritis (Guillain-Barré syndrome)\n7. Myasthenia\n8. Patient treated by continuous hemodialysis or hemofiltration for more than 72 hours following the onset of awakening.\n9. Complete transmetatarsal or higher amputation of one or both lower limbs.\n10. Protected person (under guardianship or curatorship)\n11. Person under court protection\n12. Person not affiliated to a social security scheme\n13. Pregnant or breast-feeding woman\n14. Patient already included in the study\n15. Patient taking part in an interventional clinical study, the aim of which is to show an improvement in functional level on discharge from the intensive care unit or which focuses on the theme of early rehabilitation in the intensive care unit.",{"count":166,"type":23},[58],"Chair positioning is one of a series of early mobilization techniques. At present, this technique, which involves moving a patient out of the resuscitation bed, can be performed passively or actively. It does not constitute a rehabilitative act as such, but it is considered in common paradigms as a technique to improve \"the patient's breathing and strength\".\n\nHowever, recommendations issued in 2013 by the Society of intensive care physiotherapy and the society \"Société de réanimation de langue française (SRLF)\", reveal that this chair position cannot be recommended with a high grade.\n\nThe aim of the investigators is therefore to break down this early mobilization process in intensive care, to find out whether the armchair is an indispensable tool for improving functional and muscular processes.\n\nThe research hypothesis is therefore as follows:\n\n\"Early armchairing of the resuscitation patient, improves functional recovery compared to a conservative positioning strategy (sitting in bed).\"",[616],"ICU Acquired Weakness",[618,616,619,620,621],"mechanical ventilation","Arm Chair","Sitting","Early mobility","2025-12-18",{"date":624,"type":37},"2025-12-19",{"date":626,"type":37},"2025-07-04",{"date":628,"type":23},"2028-01",{"name":43,"class":44},11,{"id":632,"slug":633,"hasResults":12,"nctId":634,"briefTitle":635,"officialTitle":636,"acronym":637,"eligibilityCriteria":638,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":639,"targetDuration":4,"studyType":56,"phases":640,"briefSummary":641,"conditions":642,"keywords":647,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":653,"completionDateStruct":655,"leadSponsor":657,"locationsCount":45},"100602946","endotracheal-suctionning-during-positive-pressure-extubation-in-icu-100602946","NCT07130123","Endotracheal Suctionning During Positive Pressure Extubation in ICU","Removal of the Intubation Tube Under Positive Pressure With or Without Endotracheal Suctioning During Extubation in Intensive Care: a Prospective Randomised Controlled Trial","INTENTION","Inclusion Criteria:\n\n* Adult patient\n* Intubated for more than 48 hours\n* Patient for whom extubation is prescribed by the patient's physician\n\nExclusion Criteria:\n\n* Headboard restriction\\>30°.\n* Decision to limit active treatment in advance of reintubation\n* Protected person (under guardianship or curatorship)\n* Person under court protection\n* Persons deprived of liberty\n* Persons not affiliated to a social security scheme\n* Pregnant or breast-feeding woman\n* No co-inclusion with a study whose period of interest is follow-up within 3 hours of extubation.",{"count":471,"type":23},[58],"The aim of this clinical trial is to evaluate endotracheal suctioning during positive pressure extubation in mechanically ventilated adult patients (over 18 years old) in the intensive care unit (ICU). The main question it aims to answer is whether the intervention improves the respiratory oxygenation index (ROX) three hours after extubation compared to no endotracheal suction during positive pressure extubation.\n\nParticipants will only need to be extubated by the nursing team in the ICU. Follow-up will consist of evaluating respiratory rate, pulse oximetry and inspired oxygen fraction for three hours following extubation.",[643,118,644,645,646],"Mechanical Ventilation With Oral Intubation","Oxygen Saturation Measurement","Rox Index","Extubation",[648,649,650],"rox index","extubation","Suctionning","2025-12-12",{"date":624,"type":37},{"date":654,"type":37},"2025-10-03",{"date":656,"type":23},"2027-10",{"name":43,"class":44},{"id":659,"slug":660,"hasResults":12,"nctId":661,"briefTitle":662,"officialTitle":663,"acronym":664,"eligibilityCriteria":665,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":666,"targetDuration":4,"studyType":56,"phases":667,"briefSummary":668,"conditions":669,"keywords":676,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":681,"startDateStruct":682,"completionDateStruct":684,"leadSponsor":686,"locationsCount":45},"100599524","neutralizing-power-of-serum-antibodies---2-100599524","NCT07085611","Neutralizing Power of Serum Antibodies - 2","Study of the Neutralizing Power of Serum Antibodies - 2 (PNAS-2)","PNAS-2","Inclusion Criteria:\n\n* Adults (≥18 years)\n* Patients receiving or scheduled to receive anti-SARS-CoV-2 and\u002For anti-MPXV vaccines or monoclonal antibodies\n* Patients have provided written informed consent\n\nExclusion Criteria:\n\n* Persons under guardianship or curatorship\n* Persons under legal protection,\n* Persons persons deprived of liberty\n* Persons not affiliated to a social security scheme\n* Pregnant or breastfeeding women",{"count":296,"type":23},[58],"Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recognized as a correlate of protection against a new infection. This study aims to describe the neutralizing power of serum and nasal antibodies over time, in relation to SARS-CoV-2 and MPXV vaccines or treatments received.",[670,671,672,673,674,675],"COVID-19","SARS-CoV-2 Viraemia","Monkey Pox","Vaccination","Serum","Mucosal Immunity",[677,678,679,673,674,680],"Neutralizing antibodies","SARS-CoV-2","Monkeypox","Mucosal immunity",{"date":624,"type":37},{"date":683,"type":37},"2025-08-22",{"date":685,"type":23},"2035-07-11",{"name":43,"class":44},""]